Boston Scientific

Boston Scientific
VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)

Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. With 24,000 employees worldwide, sales force in 40+ countries, and 15 manufacturing facilities worldwide, the company invested $895 million in R&D in 2011, with a $7.6 billion revenue.  Continue reading «Boston Scientific»

Website Share Login to Edit

Full Description

Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. With 24,000 employees worldwide, sales force in 40+ countries, and 15 manufacturing facilities worldwide, the company invested $895 million in R&D in 2011, with a $7.6 billion revenue.

 

rel="nofollow"

Address

Boston Scientific Corporate Headquarters One Boston Scientific Place Natick, MA 01760-1537, USA

Phone

+1 (508) 650-8000

Twitter username

https://twitter.com/bostonsci


Company News

  • Boston Scientific Announces Conference Call Discussing Third Quarter 2018 Financial Results

    MARLBOROUGH, Mass., Oct. 1, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2018 on Wednesday, October 24, 2018 at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer.  The company will issue a news release announcing financial results for the third quarter on Wednesday, October 24, 2018, prior to the conference call. A live webcast of the conference call will be available on the Investor Relations section ...
  • Boston Scientific Receives U.S. FDA Approval for the Eluvia™ Drug-Eluting Vascular Stent System

    First peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease MARLBOROUGH, Mass., Sept. 24, 2018 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia™ Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease (PAD). The Eluvia stent utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel for a one-year timeframe, designed to prevent tissue regrowth that might otherwis...
  • Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial

    First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries SAN DIEGO and MARLBOROUGH, Mass., Sept. 22, 2018 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were presented during a late-breaking clinical trial session at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Diego, and at the annual Cardiovascular and Interventional Radiological Soci...
  • Boston Scientific Launches LithoVue Empower™ Retrieval Deployment Device

    New Data at World Congress of Endourology Demonstrate the LithoVue Empower Device Improves OR Experience MARLBOROUGH, Mass., Sept. 21, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the global launch of the LithoVue Empower™ Retrieval Deployment Device, designed to be used with the LithoVue™ Single-Use Digital Flexible Ureteroscope and compatible nitinol retrieval basket to enable urologists to operate a ureteroscope and basket simultaneously when retrieving kidney stones via flexible ureteroscopy (URS). The LithoVue Empower Device is one of several new devices Boston Scientific is planning that addresses unmet needs and inefficiencies during stone proced...
  • Boston Scientific Announces Scheduled Presentations At Transcatheter Cardiovascular Therapeutics 2018

    MARLBOROUGH, Mass., Sept. 17, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Diego, on September 21 - September 25. Data from the head-to-head IMPERIAL trial evaluating the ELUVIA™ Drug-Eluting Vascular Stent System and the Zilver® PTX® Stent for treatment of superficial femoral or proximal popliteal lesions will be featured during a late-breaking clinical trial session on Saturday, September 22. Two-year outcomes data from the REPRISE III study, a head-to-head comparison of the LOTUS™ ...
  • Boston Scientific Announces Agreement To Acquire Augmenix, Inc.

    Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients MARLBOROUGH, Mass., Sept. 6, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy. The transaction consists of an upfront cash payment of $500 million, and up to $100 million for reaching sales-based milestones.  Each year, more tha...
  • Boston Scientific to Participate in Morgan Stanley Global Healthcare Conference

    MARLBOROUGH, Mass., Sept. 6, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 in New York City. Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer, will participate in a 30-minute question-and-answer session with the host analyst beginning at approximately 8:35 a.m. EDT. A live webcast of the session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com. A replay of the webcast will be accessible a...